Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 2Phase 1 1

Status

Completed 4Terminated 2

Sponsor Class

INDUSTRY 6

Study Type

Interventional 6

Sponsor

Cancer Type

Dermatologic 4Gastrointestinal 2Sarcoma 1

Conditions

Melanoma 4Sarcoma 1Neoplasm Metastasis 1Colorectal Neoplasms 1Advanced Pancreatic Cancer 1

Interventions

Paclitaxel 337pembrolizumab 332Carboplatin 329Cisplatin 276Gemcitabine 264Docetaxel 251Bevacizumab 239Nivolumab 230Pemetrexed 210Rituximab 183Dexamethasone 183Cyclophosphamide 169Capecitabine 169Trastuzumab 149Fluorouracil 147Ipilimumab 121atezolizumab 118Prednisone 117Erlotinib Hydrochloride 116Oxaliplatin 109Cetuximab 104Sunitinib 101Leucovorin 97Doxorubicin 97Lenalidomide 93Irinotecan 89130-nm albumin-bound paclitaxel 84durvalumab 77Bortezomib 77Azacitidine 73

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
INDUSTRY × Has results × IMM-101 × Clear all
NCT01539824 2024-11-25

A Study of IMM-101 in Combination With Radiation Induced Tumour Necrosis in Colorectal Cancer

Immodulon Therapeutics Ltd

Phase 2 Completed
12 enrolled 6 charts
Gastrointestinal

Colorectal Neoplasms

NCT03009058 2024-11-25

MODULATE

Immodulon Therapeutics Ltd

Phase 1/2 Terminated
2 enrolled 7 charts
DermatologicSarcoma

Melanoma, Neoplasm Metastasis, Sarcoma

NCT03711188 2024-04-29

A Study of IMM-101 in Combination With Checkpoint Inhibitor Therapy in Advanced Melanoma

Immodulon Therapeutics Ltd

Phase 2 Completed
16 enrolled 14 charts
Dermatologic

Melanoma

NCT01559818 2023-06-22

A Long Term Follow up Study for Patients Who Previously Took Part in the Phase I Study IMM-101-001

Immodulon Therapeutics Ltd

Phase 1/2 Terminated
10 enrolled 12 charts
Dermatologic

Melanoma

NCT01303172 2021-11-10

A Trial Comparing Gemcitabine With and Without IMM-101 in Advanced Pancreatic Cancer

Immodulon Therapeutics Ltd

Phase 2 Completed
110 enrolled 14 charts
Gastrointestinal

Advanced Pancreatic Cancer

NCT01308762 2012-12-06

A Clinical Study, to Evaluate the Safety and Tolerability of Intradermal IMM-101 in Adult Melanoma Cancer Patients

Immodulon Therapeutics Ltd

Phase 1 Completed
19 enrolled 10 charts
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡